Hisamitsu Pharmaceutical : Notice Regarding Status of Acquisition of Treasury Shares
December 04, 2023
Share
This material is an English translation of the press release announced on Dec. 5, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.
Dec. 5, 2023
Notice Regarding Status of Acquisition of Treasury Shares
(Acquisition of treasury shares in accordance with the provisions of the Articles of Incorporation pursuant to
Article 165, paragraph 2 of the Companies Act)
Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) hereby announces the status (in progress) of acquisition of treasury shares in accordance with Article 156 of the Companies Act as applied pursuant to Article 165, paragraph 3 of the same Act, as announced on July 13, 2023, as follows.
1.
Type of shares acquired Common shares of the Company
2.
Total number of shares acquired
312,500 shares
3.
Total amount of shares acquired
1,457,924,500 yen
4.
Period for acquisition
November 1, 2023 to November 30, 2023
(based on contract)
5.
Method of acquisition
Market purchase on the Tokyo Stock Exchange
(Reference)
Resolutions of the board of directors meeting held on July 13, 2023
Type of shares to be acquired: Common shares of the Company
Total number of shares that may be acquired: 2 million shares (maximum)
(Percentage of total number of shares outstanding (excluding treasury shares): 2.57%)
Total amount of shares acquired: 10 billion yen (maximum)
Period for acquisition: July 14, 2023 to February 29, 2024
Method of acquisition: Market purchase on the Tokyo Stock Exchange
Cumulative total of treasury shares acquired based on the above resolutions of the board of directors meeting (as of November 30, 2023)
(1)
Total number of shares acquired
1,633,400 shares
(2)
Total amount of shares acquired
8,140,321,900 yen
Attachments
Original Link
Original Document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 05 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 December 2023 07:14:34 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
